


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.79%
-12.16%
+5.27%
ABBV
AbbVie
$232.35
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Pays a reliable dividend
ABBV Price Performance
$223.43 (+3.99%)
$222.99 (+4.20%)
$230.5 (+0.80%)
$210.01 (+10.64%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Pays a reliable dividend
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
ABBV Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ABBV Street Sentiment is extremely bullish and have positive views on the near-term outlook
ABBV has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
Recent Upgrades and Downgrades
Feb 23, 2026
Initiate
Overweight
Barclays
Feb 20, 2026
Initiate
Overweight
Barclays
Feb 12, 2026
Reiterate
its Overweight
Cantor Fitzgerald
Jan 27, 2026
Price Target Raised
Buy
Jan 06, 2026
Price Target Raised
Buy
Morgan Stanley
PFE
Pfizer
26.61
-0.04%
SNY
Sanofi
45.00
-2.64%
LLY
Eli Lilly and
983.26
-2.02%
MRK
Merck Company
116.07
-3.50%
TEVA
Teva Pharma
31.75
-3.52%
What is ABBV current stock price?
What are ABBV stock strengths?
What is ABBV Risk Level?
What is ABBV market cap and volume?
What is ABBV current Stock IQ?
Should I buy ABBV stock right now?
Is ABBV a Strong Buy right now?
What does a 'Strong Buy' rating mean for ABBV?
What does a 'Strong Sell' rating mean for ABBV?
What factors influence ABBV's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
ABBV
AbbVie
Current Price
$232.35
Runners Also Watch
PFE
Pfizer
26.61
-0.04%
SNY
Sanofi
45.00
-2.64%
LLY
Eli Lilly and
983.26
-2.02%
MRK
Merck Company
116.07
-3.50%
TEVA
Teva Pharma
31.75
-3.52%

ABBV Price Performance
$223.43 (+3.99%)
$222.99 (+4.20%)
$230.5 (+0.80%)
$210.01 (+10.64%)
ABBV Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Pays a reliable dividend
Investors confidence is positive
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
ABBV Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ABBV Street Sentiment is extremely bullish and have positive views on the near-term outlook
ABBV has Low risk level
Average key support and resistance price levels
Overall Wall Street Rating
ABBV Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Pays a reliable dividend
ABBV Latest Analysis
AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript.
Wed Mar 4, 2026
AbbVie sees positive late-stage results for subcutaneous Skyrizi in Crohns.
Mon Mar 2, 2026
Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?. AbbVie (NYSE:ABBV) is one of the best cancer stocks to invest in now. On February 23 AbbVie (NYSE: ABBV) announced plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities. The new state-of-the-art facilities at the Illinois campus are to integrate advanced manufacturing technologies with artificial intelligence. Artificial intelligence integration is [….]
Mon Mar 2, 2026
RBC Capital Launches AbbVie (ABBV) Coverage Expects Shares to Outperform Amid Competitive Fears. AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25 RBC Capital analyst Trung Huynh initiated coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $260 price target. The analyst noted that the shares have lagged due to concerns that AbbVies beat-and-raise story [….]
Thu Feb 26, 2026
AbbVie a new outperform at RBC Capital Markets on durable growth.
Wed Feb 25, 2026
FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL. AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20 the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral fixed-duration regimen for previously untreated patients providing a new alternative to [….]
Tue Feb 24, 2026
AbbVie earmarks $380M to build two manufacturing facilities in Illinois.
Mon Feb 23, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.